# To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil

Study · id `cardio:ct-nct06465264` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06465264](<https://clinicaltrials.gov/study/NCT06465264>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06465264

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 499 participants.

## Technical summary

Registry record NCT06465264. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-29 (actual); primary completion 2022-08-16 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 499 participants (enrolled count; ClinicalTrials.gov record NCT06465264, source copy `cardio:ctgov-nct06465264-2024-06-28`, retrieved 2026-10-26)
- Started: 2021-04-29 (actual) (ClinicalTrials.gov record NCT06465264, source copy `cardio:ctgov-nct06465264-2024-06-28`, retrieved 2026-10-26)
- Primary completion: 2022-08-16 (actual) (ClinicalTrials.gov record NCT06465264, source copy `cardio:ctgov-nct06465264-2024-06-28`, retrieved 2026-10-26)
- Completion: 2023-02-24 (actual) (ClinicalTrials.gov record NCT06465264, source copy `cardio:ctgov-nct06465264-2024-06-28`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06465264, source copy `cardio:ctgov-nct06465264-2024-06-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06465264-2024-06-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil
- Condition: Essential Hypertension
- Intervention (Drug): Allisartan Isoproxil/Amlodipine group 1
- Intervention (Drug): Amlodipine group 1
- Intervention (Drug): Allisartan Isoproxil/Amlodipine group 2
- Intervention (Drug): Allisartan Isoproxil group 2
- Lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. (`cardio:org-shenzhen-salubris-pharmaceuticals-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled by Amlodipine: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomized Controlled Trial (`cardio:pubmed-39821945`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d8236e801945109b2c5ac1da9c30f9786d75a5a853c7d8181adf579140273517
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
